<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.2" xml:lang="ru" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="issn">2658-6533</journal-id><journal-title-group><journal-title>Научные результаты биомедицинских исследований</journal-title></journal-title-group><issn pub-type="epub">2658-6533</issn></journal-meta><article-meta><article-id pub-id-type="doi">10.18413/2658-6533-2021-7-4-0-5</article-id><article-id pub-id-type="publisher-id">2574</article-id><article-categories><subj-group subj-group-type="heading"><subject>Фармакология, клиническая фармакология</subject></subj-group></article-categories><title-group><article-title>&lt;strong&gt;Фармакологическая эффективность комбинированных глазных лекарственных пленок на основе левофлоксацина и декспантенола, а также дексаметазона и декспантенола при лечении инфицированных ожогов роговицы&lt;/strong&gt;&lt;br /&gt;
&amp;nbsp;</article-title><trans-title-group xml:lang="en"><trans-title>&lt;strong&gt;Pharmacological efficiency of combined eye drug films based on Levofloxacin and Dexpanthenol, and also Dexamethazone and Dexpanthenol in the treatment of infected corneal injury&lt;/strong&gt;&lt;br /&gt;
&amp;nbsp;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Ярмамедов</surname><given-names>Дмитрий Муталифович</given-names></name><name xml:lang="en"><surname>Yarmamedov</surname><given-names>Dmitry M.</given-names></name></name-alternatives><email>d-yarmamedov@yandex.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Медведева</surname><given-names>Марина Викторовна</given-names></name><name xml:lang="en"><surname>Medvedeva</surname><given-names>Marina V.</given-names></name></name-alternatives><email>mari-la2003@mail.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Липатов</surname><given-names>Вячеслав Александрович</given-names></name><name xml:lang="en"><surname>Lipatov</surname><given-names>Vyacheslav A.</given-names></name></name-alternatives><email>drli@yandex.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Затолокина</surname><given-names>Мария Алексеевна</given-names></name><name xml:lang="en"><surname>Zatolokina</surname><given-names>Maria A.</given-names></name></name-alternatives><email>marika1212@mail.ru</email></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="ru"><surname>Ярмамедова</surname><given-names>Оксана Муталифовна</given-names></name><name xml:lang="en"><surname>Yarmamedova</surname><given-names>Oksana M.</given-names></name></name-alternatives><email>oksana.yarmamedova@mail.ru</email></contrib></contrib-group><pub-date pub-type="epub"><year>2021</year></pub-date><volume>7</volume><issue>4</issue><fpage>0</fpage><lpage>0</lpage><self-uri content-type="pdf" xlink:href="/media/medicine/2021/4/Биомед_исследования-72-83.pdf" /><abstract xml:lang="ru"><p>Актуальность: При лечении инфицированных ожогов роговицы часть пациентов не способна соблюдать график частых инстилляций лекарственных препаратов, что влечет за собой стойкое необратимое снижение остроты зрения из-за формирования помутнений роговицы. Цель исследования: Повышение эффективности лечения инфицированных ожогов роговицы с использованием комбинированных глазных лекарственных пленок на основе левофлоксацина и декспантенола, а также дексаметазона и декспантенола. Материалы и методы: Спустя 1 час после формирования стандартного инфицированного ожога роговицы в группе сравнения проводили лечение по классической методике с использованием инстилляций, а в экспериментальной группе проводили терапию с использованием комбинированных глазных лекарственных пленок на основе левофлоксацина и декспантенола, а также дексаметазона и декспантенола. Фиксировалась площадь дефекта эпителия роговицы. Морфологическое исследование с окраской гематоксилин-эозином проводили по стандартной методике на различных сроках наблюдения. Результаты: Зафиксирована выраженная клеточная реакция уже спустя 1 час после формирования стандартного инфицированного ожога роговицы. Площадь дефекта эпителия роговицы уменьшалась быстрее в группе с лечением с использованием комбинированных глазных лекарственных пленок. Толщина наружного эпителия роговицы, а также количество клеток в его слоях нормализовалось на 3 сутки в экспериментальной группе, а в группе сравнения с лечением по стандартной методике на 5 сутки эксперимента. При исследовании толщины эндотелия роговицы не было зафиксировано статистически значимых отличий от нормальной роговицы. Заключение: При лечении стандартного инфицированного ожога роговицы применение комбинированных глазных лекарственных пленок позволяет сократить процесс морфологического восстановления роговицы до 3 суток, в сравнении с лечением с использованием инстилляций, где восстановление роговицы к показателям интактного глаза наступает на 5 сутки.

&amp;nbsp;</p></abstract><trans-abstract xml:lang="en"><p>Background:&amp;nbsp;When treating infected corneal burns, some patients are not able to comply with the schedule of frequent instillations of drugs, which entails a persistent irreversible decrease in visual acuity due to the formation of corneal opacities. The aim of the study:&amp;nbsp;To increase the effectiveness of treatment of infected corneal burns using combined ophthalmic medicinal films based on Levofloxacin and Dexpanthenol, as well as Dexamethasone and Dexpanthenol. Materials and methods:&amp;nbsp;1 hour after the formation of a standard infected corneal burn, the comparison group was treated according to the classical method using instillations, and the experimental group was treated with combined ophthalmic medicinal films based on Levofloxacin and Dexpanthenol, as well as Dexamethasone and Dexpanthenol. The area of the defect in the corneal epithelium was recorded. Morphological examination with hematoxylin-eosin staining was carried out according to the standard technique at different periods of observation. Results:&amp;nbsp;A pronounced cellular reaction was recorded already 1 hour after the formation of a standard infected corneal burn. The defect area of the corneal epithelium decreased faster in the group treated with combined ophthalmic drug films. The thickness of the outer corneal epithelium, as well as the number of cells in its layers, returned to normal on the 3rd day in the experimental group, and in the comparison group with treatment according to the standard method on the 5th day of the experiment. When examining the thickness of the corneal endothelium, there were no statistically significant differences from the normal cornea. Conclusion:&amp;nbsp;In the treatment of a standard infected corneal burn, the use of combined ophthalmic medicinal films can reduce the process of morphological restoration of the cornea to 3 days, in comparison with treatment using instillations, where the cornea is restored to the parameters of an intact eye on the 5th day.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ожог роговицы</kwd><kwd>глазные лекарственные пленки</kwd><kwd>левофлоксацин</kwd><kwd>дексаметазон</kwd><kwd>декспантенол</kwd></kwd-group><kwd-group xml:lang="en"><kwd>corneal burns</kwd><kwd>ophthalmic medicinal films</kwd><kwd>Levofloxacin</kwd><kwd>Dexamethasone</kwd><kwd>Dexpanthenol</kwd></kwd-group></article-meta></front><back><ref-list><title>Список литературы</title><ref id="B1"><mixed-citation>Porth JM, Deiotte E, Dunn M, et al. A Review of the Literature on the Global Epidemiology of Corneal Blindness. . 2019;38(12):1602-1609. DOI: https://doi.org/10.1097/ICO.0000000000002122</mixed-citation></ref><ref id="B2"><mixed-citation>World Health Organization: World report on vision [Internet]. 2019 [updated 2019 Fall; cited 2020 Sep 18]. Available from: https://www.who.int/publications/i/item/world-report-on-vision</mixed-citation></ref><ref id="B3"><mixed-citation>Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis. The Lancet Global Health. 2017;5(12):1221-1234. DOI: https://doi.org/10.1016/S2214-109X(17)30393-5</mixed-citation></ref><ref id="B4"><mixed-citation>Sabanayagam C, Cheng CY. Global causes of vision loss in 2015: are we on track to achieve the Vision 2020 target? The Lancet Global Health. 2017;5(12):e1164-e1165. DOI: https://doi.org/10.1016/S2214-109X(17)30412-6</mixed-citation></ref><ref id="B5"><mixed-citation>Deguchi H, Kitazawa K, Kayukawa K, et al. The trend of resistance to antibiotics for ocular infection of Staphylococcus aureus, coagulase-negative staphylococci, and corynebacterium compared with 10-years previous: A retrospective observational study. PLoS ONE. 2018;13(9):e0203705. DOI: https://doi.org/10.1371/journal.pone.0203705</mixed-citation></ref><ref id="B6"><mixed-citation>Jin H, Parker WT, Law NW, et al. Evolving risk factors and antibiotic sensitivity patterns for microbial keratitis at a large county hospital. British Journal of Ophthalmology. 2017;101:1483-1487. DOI: https://doi.org/10.1136/bjophthalmol-2017-311441</mixed-citation></ref><ref id="B7"><mixed-citation>Silvester A, Neal T, Czanner G, et al. Adult bacterial conjunctivitis: resistance patterns over 12 years in patients attending a large primary eye care centre in the UK. BMJ Open Ophthalmology. 2016;1(1):e000006. DOI: http://dx.doi.org/10.1136/bmjophth-2016-000006</mixed-citation></ref><ref id="B8"><mixed-citation>Wozniak RA, Aquavella JV. Antibiotics in ophthalmology practice. Expert Review of Ophthalmology. 2017;12(3):243-250. DOI: https://doi.org/10.1080/17469899.2017.1318065</mixed-citation></ref><ref id="B9"><mixed-citation>Taylor HR. Global blindness: the progress we are making and still need to make. Asia-Pacific Journal of Ophthalmology. 2019;8(6):424-428. DOI: https://doi.org/10.1097/APO.0000000000000264</mixed-citation></ref><ref id="B10"><mixed-citation>Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of disease study 2016. The Lancet. 2017;390(10100):1211-1259. DOI: https://doi.org/10.1016/S0140-6736(17)32154-2</mixed-citation></ref><ref id="B11"><mixed-citation>Bizrah M, Yusuf A, Ahmad S. An update on chemical eye burns. Eye. 2019;33(9):1362-1377. DOI: https://doi.org/10.1038/s41433-019-0456-5</mixed-citation></ref><ref id="B12"><mixed-citation>Toriyama K, Suzuki T, Shiraishi A. Characteristics of infectious keratitis in old and very old patients. Journal of Ocular Pharmacology and Therapeutics. 2018;34(8):565-569. DOI: https://doi.org/10.1089/jop.2018.0028&amp;nbsp;</mixed-citation></ref><ref id="B13"><mixed-citation>Yarmamedov D, Lipatov V, Medvedeva M, et al. Study of the pharmacological impact of polymeric membranes with antibacterial effect in traumatic lesions of cornea. Research Results in Pharmacology. 2018;4(4):89-96. DOI: https://doi.org/10.3897/rrpharmacology.4.31006</mixed-citation></ref><ref id="B14"><mixed-citation>Barrientez B, Nicholas SE, Whelche A, et al. Corneal injury: clinical and molecular aspects. Experimental Eye Research. 2019;186:107709. DOI: https://doi.org/10.1016/j.exer.2019.107709</mixed-citation></ref><ref id="B15"><mixed-citation>Moghadam MR, Jafarinasab MR, Yousefi Z, et al. Aloe vera gel-derived eye drops for alkaline corneal injury in a rabbit model. Journal of Ophthalmic and Vision Research. 2020;15(1):7-15. DOI: https://doi.org/10.18502/jovr.v15i1.5932</mixed-citation></ref><ref id="B16"><mixed-citation>The Association for Research in Vision and Ophthalmology [Internet]. Statement for the use of animals in ophthalmic and vision research [updated 2016 Fall; cited 2020 Sep 18]. Available from: https://www.arvo.org/About/policies/statement-for-the-use-of-animals-in-ophthalmic-and-vision-research</mixed-citation></ref><ref id="B17"><mixed-citation>American Academy of Ophthalmology [Internet]. Chemical (Alkali and Acid) Injury of the conjunctiva and cornea [updated 2020 Sep 13; cited 2020 Sep 22]. Available from: https://eyewiki.org/Chemical_(Alkali_and_Acid)_Injury_of_the_Conjunctiva_and_Cornea</mixed-citation></ref><ref id="B18"><mixed-citation>Kanski J, Bowling B. Kanski&amp;#39;s Clinical ophthalmology. 8 ed. Saunders Ltd; 2018.</mixed-citation></ref><ref id="B19"><mixed-citation>Medscape [Internet]. Corneal abrasion treatment &amp;amp; management [updated 2019 Jan 3; cited 2020 Sep 12]. Available from: https://emedicine.medscape.com/article/1195402-treatment</mixed-citation></ref><ref id="B20"><mixed-citation>Willmann D, Fu L, Melanson SW. Corneal injury. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 [cited 2020 Sep 22]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459283</mixed-citation></ref><ref id="B21"><mixed-citation>Азнабаев МТ, Азаматова ГА. Метод профилактики внутриглазных инфекций после факоэмульсификации катаракты с помощью глазной лекарственной пленки с левофлоксацином. Вестник Оренбургского государственного университета. 2010;12(118):8-10.</mixed-citation></ref><ref id="B22"><mixed-citation>Гайсина ГЯ, Азнабаев МТ, Азаматова ГА, и др. Изучение терапевтического эффекта глазных лекарственных пленок с моксифлоксацином на модели экзогенного бактериального воспаления глаз. Медицинский вестник Башкортостана. 2015;2(10):126-129.</mixed-citation></ref></ref-list></back></article>